NDA 219083 · Cytokinetics
Myqorzo
Aficamten · Oral
NovelBreakthrough therapyOrphanCDER novel approval, Dec 19, 2025: To treat symptomatic obstructive hypertrophic cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Dec 19, 2025
Approved uses
2
Original approval plus efficacy supplements
Registered trials
12
7 Phase 3, 1 recruiting
FAERS reports
497
159 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF HEART FAILURE MYQORZO reduces left ventricular ejection fraction (LVEF) and can cause heart failure due to systolic dysfunction [see Warnings and Precautions (5.1) ]. Echocardiogram assessments are required prior to and during treatment with MYQORZO to monitor for systolic dysfunction. Initiation of MYQORZO in patients with LVEF <55% is not recommended. Decrease the dose of MYQORZO if LVEF is <50% and ≥40% [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ] . Interrupt the dose of MYQORZO if LVEF <40% or if the patient experiences heart failure symptoms or worsening clinical status due to systolic dysfunction [see Dosage and Administration (2.2) ]. Because of the risk of heart failure due to systolic dysfunction, MYQORZO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the MYQORZO REMS...
What it is approved for
From the label in effect Dec 16, 2025.
MYQORZO is indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. ( 1 )
Mechanism: Aficamten is an allosteric and reversible inhibitor of cardiac myosin motor activity. Aficamten reduces the force generated by myosin at the cardiac sarcomere, which contributes to the pathophysiology of HCM. In patients with HCM, myosin inhibition with aficamten reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2026 Supplement 2 · Efficacy OrphanLabelMedication Guide
- Dec 19, 2025 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
4 products under this application
- MYQORZO · AFICAMTEN 20MG · TABLET, ORAL · Prescription
- MYQORZO · AFICAMTEN 10MG · TABLET, ORAL · Prescription
- MYQORZO · AFICAMTEN 15MG · TABLET, ORAL · Prescription
- MYQORZO · AFICAMTEN 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Aficamten" as an intervention, any sponsor and status, largest first.
- Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMPivotal-lookingEnrolling by invitation
CytokineticsIndustry
NCT04848506 · 900 participants (planned) · Start May 6, 2021 · Primary completion Mar 2029
Drug: Aficamten (5 - 20 mg) · For: Symptomatic Hypertrophic Cardiomyopathy (HCM)
Sites: Birmingham, Alabama; Anchorage, Alaska; Phoenix, Arizona · 141 sites in all
- A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)Pivotal-lookingActive, not recruiting
CytokineticsIndustry
NCT06081894 · 500 participants (planned) · Start Aug 31, 2023 · Primary completion Aug 31, 2026
Drug: Aficamten; Placebo · For: Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 180 sites in all
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMPivotal-lookingCompleted
CytokineticsIndustry
NCT05186818 · 282 participants · Start Feb 1, 2022 · Primary completion Nov 10, 2023
Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg); Placebo to match aficamten · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sites: Anchorage, Alaska; La Jolla, California; Los Angeles, California · 114 sites in all
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMPivotal-lookingCompleted
CytokineticsIndustry
NCT05767346 · 175 participants · Start Jun 20, 2023 · Primary completion Feb 28, 2025
Drug: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg); Placebo to match aficamten and 2 more · For: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Sites: Anchorage, Alaska; Phoenix, Arizona; La Jolla, California · 71 sites in all
- A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsPivotal-lookingCompleted
CytokineticsIndustry
NCT03767855 · 114 participants · Start Dec 4, 2018 · Primary completion Jan 3, 2020
Drug: CK-3773274 - Granules in Capsule; Placebo - Granules in Capsule and 1 more · For: Symptomatic Obstructive Hypertrophic Cardiomyopathy; Healthy Subjects
Sites: Tempe, Arizona
CytokineticsIndustry
NCT04219826 · 96 participants · Start Jan 10, 2020 · Primary completion Feb 28, 2023
Drug: CK-3773274 (5 - 15 mg); CK-3773274 (10 - 30 mg) and 1 more · For: Hypertrophic Cardiomyopathy (HCM)
Sites: Los Angeles, California; San Francisco, California; Evanston, Illinois · 22 sites in all
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).Pivotal-lookingActive, not recruiting
CytokineticsIndustry
NCT06412666 · 65 participants (planned) · Start May 29, 2024 · Primary completion Jan 2030
Drug: Aficamten; Placebo · For: Pediatric; Symptomatic Obstructive Hypertrophic Cardiomyopathy
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 36 sites in all
CytokineticsIndustry
NCT05924815 · 44 participants · Start May 15, 2023 · Primary completion Nov 14, 2023
Drug: Aficamten; Aficamten-matching Placebo and 1 more · For: Healthy Participants
Sites: Tempe, Arizona
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea58
- fatigue45
- dizziness44
- product dose omission issue44
- blood pressure increased33
- chest pain33
- headache26
- product use issue22
- atrial fibrillation17
- peripheral swelling17
- drug ineffective16
- asthenia15
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 497 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Maron MS, Masri A, Nassif ME, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Garcia-Pavia P, Maron MS, Masri A, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy.
Davis BJ, Volk H, Nguyen O, et al. · J Am Heart Assoc 2025 · Systematic Review, Research Support, Non-U.S. Gov't
- Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Saberi S, Abraham TP, Choudhury L, et al. · JACC Heart Fail 2025 · Clinical Trial, Phase III, Clinical Trial, Phase II
- Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Coats CJ, Masri A, Nassif ME, et al. · J Am Heart Assoc 2024 · Clinical Trial, Phase III, Multicenter Study
- Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.
Maron MS, Masri A, Nassif ME, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Cytokinetics
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.